Log in
Log in
E-mail
Password

Show password
Remember
Forgot password ?
Become a member for free
Sign up
Become a member for free
Sign up
New member
Sign up for FREE
New customer
Discover our services
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Lonza Group AG
  6. News
  7. Summary
    LONN   CH0013841017

LONZA GROUP AG

(LONN)
  Report
Delayed Swiss Exchange  -  11:31 2022-06-30 am EDT
509.00 CHF   +0.91%
06/26Lonza Signs License Deal With Adva Biotechnology For Automated Bioreactor-linked Patents
MT
06/24LONZA : and Adva Biotechnology Ltd. Agree to Expand Availability and Use of Automated Bioreactors with License to Lonza's Patents
PU
06/15Lonza Group Signs Manufacturing Agreement With Pierre Fabre
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

LONZA GROUP AG : Ex-dividend day for final dividend

05/09/2022 EDT
share with twitter
share with LinkedIn
share with facebook

A final dividend is removed today from Lonza Group AG's share.



© Factset 2022
All news about LONZA GROUP AG
06/26Lonza Signs License Deal With Adva Biotechnology For Automated Bioreactor-linked Patent..
MT
06/24LONZA : and Adva Biotechnology Ltd. Agree to Expand Availability and Use of Automated Bior..
PU
06/15Lonza Group Signs Manufacturing Agreement With Pierre Fabre
MT
06/08Lonza Rolls Out PyroCell Monocyte Activation Test System For In Vitro Testing
MT
06/07LONZA : More Sensitive Non-endotoxin Pyrogen Detection Now Possible with Lonza's New PyroC..
PU
06/03AlphaValue/Baader Europe Lifts Price Target on Lonza Group, Maintains Add Recommendatio..
MT
06/01Lonza Delivers Early Phase Clinical Manufacturing Facility in US
MT
06/01LONZA : Completes Dedicated Early Clinical Phase Development and Manufacturing Facility in..
PU
05/25Lonza and Israel Biotech Fund Collaboration Framework Agreement to Support Biologics an..
AQ
05/24Lonza Ties Up With Israel Biotech Fund On Biologics, Small Molecule Development, Manufa..
MT
More news
Analyst Recommendations on LONZA GROUP AG
More recommendations
Financials
Sales 2022 6 150 M 6 440 M 6 440 M
Net income 2022 1 068 M 1 118 M 1 118 M
Net cash 2022 255 M 267 M 267 M
P/E ratio 2022 35,4x
Yield 2022 0,65%
Capitalization 37 762 M 39 547 M 39 547 M
EV / Sales 2022 6,10x
EV / Sales 2023 5,43x
Nbr of Employees 16 218
Free-Float 99,6%
Chart LONZA GROUP AG
Duration : Period :
Lonza Group AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends LONZA GROUP AG
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 20
Last Close Price 509,00 CHF
Average target price 789,01 CHF
Spread / Average Target 55,0%
EPS Revisions
Managers and Directors
Pierre-Alain Ruffieux Chief Executive Officer
Philippe Deecke Chief Financial Officer
Albert M. Baehny Chairman
Stefan Stoffel Head-Small Molecules Exclusive Synthesis Operation
Barbara May Richmond Independent Director
Sector and Competitors
1st jan.Capi. (M$)
LONZA GROUP AG-33.77%39 234
MODERNA, INC.-43.77%56 804
IQVIA HOLDINGS INC.-24.11%40 527
SEAGEN INC.15.82%32 961
CELLTRION, INC.-9.85%18 726
ICON PUBLIC LIMITED COMPANY-29.85%17 663